How Myelodysplastic Syndrome Is Monitored Over Time: Blood Counts, Marrow Checks and Visits

A man in his seventies sits in a hospital cafe with a printout folded into quarters. Three lines are circled in blue pen: hemoglobin, neutrophils, platelets. He has been circling the same three lines every six weeks for two years. Nobody told him to do it. He simply wanted to know, before anyone else did, whether the numbers were drifting.

That habit captures what living with myelodysplastic syndrome, or MDS, mostly involves. Not surgery, not a hospital stay, but a long conversation held in numbers. MDS follow-up blood counts are the spine of that conversation: cheap, repeatable and surprisingly informative when read as a trend rather than a single snapshot.

This explainer walks through what those counts measure, why some people are watched and others are treated, when the more uncomfortable bone marrow check gets repeated, and which changes should prompt a call rather than a wait for the next appointment.

What MDS follow-up blood counts actually measure

Myelodysplastic syndrome is a group of conditions in which the bone marrow, the spongy tissue inside bones that makes blood, produces cells that are faulty, too few, or both. The Mayo Clinic describes it plainly: immature cells in the marrow fail to mature properly, so healthy blood cells never reach the bloodstream in normal numbers.

The complete blood count, usually shortened to CBC, is the test that measures how many of each cell type are circulating. Three lines carry most of the weight in MDS. Hemoglobin is the oxygen-carrying protein inside red cells; when it falls, fatigue and breathlessness follow. Neutrophils are the white cells that fight bacterial infection; when they drop, minor infections can become serious. Platelets are the cell fragments that plug leaks in blood vessels; when they run low, bruising and bleeding appear.

Two additions matter. The peripheral blood smear, a drop of blood examined under a microscope, lets a hematologist see the shape of cells rather than just the count. Dysplasia, which means abnormal appearance, shows up here as oddly sized red cells, neutrophils with too few granules, or fragments of immature cells. The smear can also reveal blasts, which are very immature marrow cells that should be rare or absent in normal blood.

The value of these counts in MDS lies in repetition. A single hemoglobin of 9.5 grams per deciliter tells a clinician one thing; a hemoglobin that has slipped from 11 to 9.5 across four visits tells them something far more useful. Reference ranges vary slightly between laboratories, so most teams ask that follow-up bloods be drawn at the same lab whenever practical, precisely so the trend is not blurred by different machines.

Is MDS a blood cancer, and why the answer shapes monitoring

Yes. MDS is classified as a cancer of the blood-forming cells. The NHS describes myelodysplasia as a type of blood cancer, and the Mayo Clinic notes that in some people it progresses to acute myeloid leukemia, an aggressive cancer of immature blood cells. That label often surprises people, because MDS rarely behaves the way most people imagine cancer behaving. There is no lump, no scan showing a mass, and for many people no symptoms for months or years.

The cancer classification matters for monitoring in three concrete ways. First, it means MDS is a clonal disease: the faulty cells descend from a single ancestor carrying acquired genetic changes. Clones can gain new mutations over time, and that possibility is why teams watch for shifts rather than assuming stability. Second, the disease sits on a spectrum. At one end are people whose counts are only mildly low and who may never need treatment beyond observation. At the other end are people whose marrow contains a growing proportion of blasts and who are closer to leukemia. Monitoring is the tool that locates a person on that spectrum and notices when they move.

Third, the cancer label brings MDS under formal risk-scoring systems. The Revised International Prognostic Scoring System, or IPSS-R, published in Blood in 2012, combines marrow blast percentage, chromosome findings, hemoglobin, platelet count and neutrophil count into a score with five risk groups: very low, low, intermediate, high and very high. Because three of those five inputs come directly from a routine blood count, the humble CBC is doing more than measuring symptoms. It is continuously re-checking the very ingredients that define a person’s risk category.

How MDS monitoring works, step by step

A typical follow-up visit is undramatic, which is rather the point. Blood is drawn, often a day or two before the appointment so results are ready. The CBC is run by an automated analyzer, and if anything looks unusual a technologist or hematologist reviews a smear by hand. Additional tubes may be sent for ferritin, a protein that reflects stored iron, for kidney and liver function, and sometimes for vitamin B12 and folate, since deficiencies of these can mimic MDS and lower counts independently.

In the consultation, the clinician usually does four things. They compare the new counts with the full history, not just the last result. They ask about symptoms that map onto the three cell lines: tiredness and breathlessness for red cells, fevers and infections for neutrophils, bruising and bleeding for platelets. They review any transfusions since the last visit, because transfusion frequency is itself a monitoring signal; needing red cells every three weeks instead of every six is a change even when the pre-transfusion hemoglobin looks similar. Finally, they decide whether anything has changed enough to warrant a repeat marrow examination, a new treatment discussion, or simply another appointment.

Bone marrow examination, when it is needed, involves two related samples taken under local anesthetic, usually from the back of the pelvis. The aspirate is liquid marrow drawn through a needle and spread on slides; it shows what percentage of cells are blasts and how dysplastic the cells look. The biopsy is a small core of bone and marrow that shows how densely packed the marrow is and whether scarring, called fibrosis, is present. Samples are also sent for cytogenetics, which examines chromosomes, and increasingly for molecular testing, which looks for specific gene mutations. The Mayo Clinic lists these as the core diagnostic steps, and follow-up marrows repeat the same panel so results can be compared like for like.

Who is watched, who is treated, and who is asked to wait

Not everyone with MDS needs treatment at diagnosis, and this is one of the harder ideas to sit with. The NHS describes a watch-and-wait approach for people whose counts are only mildly reduced and who have no troublesome symptoms. In practice, watchful waiting is not passive; it is a structured schedule of blood counts and visits with clear triggers for action agreed in advance.

People in the IPSS-R very low and low risk groups are the ones most often observed. Their marrow blast percentage is small, their chromosome findings fall into favorable categories, and their counts sit above the thresholds that define severe cytopenia. The 2012 IPSS-R paper set those thresholds: hemoglobin scored differently above 10, between 8 and 10, and below 8 grams per deciliter; platelets above 100, between 50 and 100, and below 50 (measured in thousands per microliter); and neutrophils above or below 0.8 (thousands per microliter). A person comfortably above all three lines with few blasts may reasonably be watched.

Treatment discussions tend to begin when one of three things happens. Symptoms attributable to low counts start to affect daily life, most commonly fatigue from anemia. Transfusion needs begin or increase. Or the marrow shows a rising blast percentage or new high-risk chromosome or gene changes, moving the person into an intermediate, high or very high risk group where the balance shifts toward active therapy.

Who is asked to wait is equally instructive. Someone whose anemia turns out to be driven partly by iron or B12 deficiency, kidney disease, or a medication may be asked to correct that first and re-test, because treating MDS for a problem that is not MDS helps no one. Similarly, a person who has recently recovered from an infection or received chemotherapy for another condition may have temporarily depressed counts, and teams often prefer a repeat CBC after several weeks before drawing conclusions. The decision always rests with the treating hematologist, who weighs risk group, symptoms, other health conditions and the person’s own priorities.

What labs are abnormal with MDS, and how MDS blood test results shift over time

The most searched question about MDS is also the most practical: which numbers go wrong? The honest answer is that any of the three main cell lines can be low, alone or in combination, and the pattern differs from person to person.

Anemia is the most common finding, and MedlinePlus notes that low red cell counts are the usual reason MDS is first suspected. The red cells are often larger than normal, which shows up as a raised mean corpuscular volume, or MCV, on the CBC. Neutropenia, meaning low neutrophils, is next. Thrombocytopenia, meaning low platelets, is the third. When all three are low, the term is pancytopenia.

Several results beyond the headline counts carry information. A raised reticulocyte count would suggest the marrow is trying hard to make red cells; in MDS it is often inappropriately low for the degree of anemia, a clue that production rather than loss is the problem. Lactate dehydrogenase, or LDH, an enzyme released from damaged cells, may be raised. Ferritin rises steadily in anyone receiving regular red cell transfusions, and the NHS notes that iron overload from transfusions can itself harm the heart and liver, which is why ferritin joins the routine panel once transfusions begin.

Over time, teams look for direction rather than absolute value. A hemoglobin of 9 that has been 9 for eighteen months is a very different situation from a hemoglobin of 9 that was 12 a year ago. The same applies to blasts on the smear: a person whose blood has never shown blasts and suddenly does needs a marrow look, even if the counts have not moved much. Results also wobble for ordinary reasons. Dehydration concentrates the blood and nudges hemoglobin up; a cold can transiently push neutrophils either way. This is why a single unexpected result usually earns a repeat draw before anything else.

How often are MDS follow-up blood counts checked?

People want a number, and it would be dishonest to pretend one exists. Major patient resources including the NHS and Mayo Clinic describe regular blood tests during observation and during treatment, but they deliberately do not specify a fixed interval. The reason is that the right frequency depends on at least five variables that differ between individuals.

Risk group is the first. Someone in a very low risk group with stable counts and no symptoms may be seen at long intervals of several months, because the chance of meaningful change between visits is small. Someone in a high risk group is typically checked far more often. Stability is the second: a person whose counts have not budged across many visits earns longer gaps, while anyone with a recent dip gets a shorter one. Treatment is the third. Certain therapies lower counts before they raise them, so the first cycles are usually accompanied by weekly or even twice-weekly bloods, easing off once the pattern is understood.

Transfusion dependence is the fourth variable. A person receiving red cells needs a pre-transfusion hemoglobin each time, so their blood is being counted on the transfusion schedule regardless of anything else. Other health conditions are the fifth; kidney disease or heart failure can change how the body tolerates anemia and may prompt closer watching.

What the evidence does support is the principle behind the schedule. The International Working Group response criteria for MDS, published in Blood in 2006, define a meaningful improvement in blood counts as one that is sustained for at least eight weeks. That eight-week figure is a useful anchor for patients: it explains why a good result at one visit does not change the plan, and why teams often want two or three consecutive counts pointing the same way before calling a change real. Ask your team what interval they have chosen and, more importantly, what would make them shorten it.

Blood counts, marrow checks and genetic tests compared

Each monitoring tool answers a different question, and knowing which is which makes the plan feel less arbitrary. A blood count asks how the marrow is performing today. A marrow examination asks what the marrow looks like and how many blasts it contains. Genetic testing asks what the clone is made of and whether it has changed.

Test	What it shows	How it is done	How often in follow-up
Complete blood count and smear	Hemoglobin, neutrophil and platelet levels; cell shape; presence of blasts in blood	Standard venous blood draw	Every visit; interval set by risk, stability and treatment
Ferritin and iron studies	Iron stores; risk of transfusion-related iron overload	Same blood draw	Regularly once transfusions begin
Bone marrow aspirate and biopsy	Blast percentage, dysplasia, marrow cellularity, fibrosis	Needle sampling from pelvis under local anesthetic	Not routine; repeated when counts change, before or after treatment decisions, or if progression is suspected
Cytogenetics	Chromosome gains, losses and rearrangements	From marrow sample	With each marrow examination
Molecular gene testing	Specific acquired mutations in the clone	From marrow or sometimes blood	At diagnosis and selectively at re-evaluation

The table reflects mainstream practice described by the Mayo Clinic and the NHS, but the right-hand column is deliberately non-numeric because published patient guidance does not fix intervals. One trend worth knowing about: several of the top research topics in this field concern tracking mutations in blood rather than marrow, which could eventually reduce how often needles into bone are needed. That work is promising but not yet standard, and no patient should expect it to replace marrow checks today.

Bone marrow biopsy frequency in MDS: when is a repeat needed?

Nobody enjoys a marrow examination, and the good news is that in stable MDS it is not a routine calendar event. The Mayo Clinic describes marrow aspiration and biopsy as the test that confirms the diagnosis and characterizes the disease; follow-up marrows are done for a reason, not on a timer.

Four situations commonly prompt a repeat. The first is an unexplained change in blood counts, especially a fall in more than one cell line or the appearance of blasts on the smear. The second is a treatment decision point: before starting a therapy that acts on the marrow, teams want a fresh baseline so they can later judge response, and after a set number of cycles they often re-sample to see whether blast percentage and dysplasia have improved. The 2006 International Working Group criteria define marrow response partly by blast percentage, so a follow-up marrow is the only way to formally assess that outcome. The third is suspicion of progression, discussed in the next section. The fourth is preparation for stem cell transplant, where a current marrow picture is required for planning.

What a repeat marrow adds over blood alone is specific. Blast percentage in the marrow is a core IPSS-R input with thresholds at 2, 5 and 10 percent in the 2012 Blood paper, and blood counts cannot measure it. Cytogenetics can reveal a new chromosome abnormality that changes the risk group even when counts look unchanged. Fibrosis, which can explain a marrow that is failing despite adequate cell numbers, is only visible on the core biopsy.

The procedure itself takes about twenty to thirty minutes in most clinics, is performed with local anesthetic, and leaves a small bruise and a few days of dull ache. People taking blood thinners or with very low platelets need individual advice beforehand. If you are asked to have a repeat marrow, it is reasonable to ask which of the four triggers applies and what result would change the plan.

What are the signs that MDS is progressing?

Progression in MDS has a technical meaning and a lived one, and they do not always arrive together. Technically, progression means the clone is gaining ground: more blasts in the marrow or blood, new chromosome or gene abnormalities, or a shift to a higher IPSS-R group. The 2006 International Working Group criteria formally describe disease progression in terms of rising blast percentage and worsening cytopenias, and transformation to acute myeloid leukemia when blasts reach the threshold pathologists use to define acute leukemia, which in the current international classification is 20 percent. The Mayo Clinic lists this transformation among the recognized complications of MDS.

On the blood count, the early signs are usually quiet. Counts that had plateaued begin to fall, often in more than one line at once. Transfusion intervals shorten. Blasts that were never present on the smear start to appear. A previously normal MCV or LDH drifts. None of these alone is proof, which is why they trigger a marrow examination rather than a conclusion.

In daily life, progression can announce itself through the symptoms of deepening cytopenia: fatigue that no longer lifts with a transfusion, infections that recur or linger, bruising in places that were not knocked, bleeding gums or nosebleeds that take longer to stop. Less often, people notice fevers without an obvious source, night sweats, unintended weight loss or bone discomfort. These are non-specific and can have many causes, so they are prompts to contact the team rather than reasons to assume the worst.

Two reassurances are grounded in evidence. First, the NHS and Mayo Clinic both note that many people with lower-risk MDS never progress to leukemia. Second, the whole architecture of monitoring exists so that progression, if it occurs, is caught on a blood count before it becomes an emergency. A rising trend across several visits gives the team time to re-stage and discuss options, which is precisely what the man with the blue pen in the cafe was quietly counting on.

How often is MDS misdiagnosed, and why the picture can be blurry

People search this question hoping for a percentage. There is no reliable single figure in mainstream guidance, and quoting one would be inventing certainty. What the evidence does support is that MDS is genuinely difficult to diagnose, and that both under- and over-diagnosis happen, particularly in lower-risk disease where changes are subtle.

The difficulty has a clear mechanism. Dysplasia, the abnormal cell appearance that defines MDS, is not unique to MDS. The MedlinePlus overview and the Mayo Clinic both emphasize that diagnosis requires excluding other causes of low counts. Vitamin B12 or folate deficiency, heavy alcohol use, certain medications, viral infections, thyroid disease, copper deficiency and recent chemotherapy can all produce marrow cells that look dysplastic under the microscope. A hematopathologist interpreting a marrow slide from someone with an uncorrected B12 deficiency may see changes indistinguishable from early MDS.

Chromosome and gene testing has sharpened the picture but added a new grey zone. Some acquired mutations found in MDS also appear in healthy older adults without any blood count abnormality, a state sometimes called clonal hematopoiesis of indeterminate potential. Finding a mutation therefore does not by itself confirm MDS; the diagnosis still rests on persistent low counts plus dysplasia or a defining genetic change, with alternatives excluded.

Diagnostic uncertainty is one more reason follow-up blood counts matter so much. When a marrow is borderline, teams often choose to repeat the CBC over several months rather than label prematurely. A person whose counts normalize after B12 replacement did not have MDS; a person whose counts keep sliding despite everything being corrected probably does. If your own diagnosis was described as early, borderline or presumed, it is entirely reasonable to ask whether a second pathology review or a repeat marrow is planned, and how the team will confirm the label over time.

Monitoring during treatment: what the following weeks usually look like

Once treatment begins, the rhythm of monitoring changes and often intensifies, at least at first. The Mayo Clinic groups MDS treatments into supportive care, which includes transfusions and growth factors, medicines that act on the marrow, and stem cell transplant for selected people. Each brings its own monitoring pattern, and each decision sits with the prescribing hematologist.

Supportive care is the most common. Red cell transfusions are given when hemoglobin falls below a threshold agreed with the team or when symptoms demand it, so a pre-transfusion count is drawn each time. Platelet transfusions are typically reserved for bleeding or very low counts. Ferritin is followed because every unit of red cells carries iron the body cannot excrete, and the NHS notes that iron overload can damage organs over years; medicines that bind and remove iron, known as chelators, may be discussed once ferritin climbs, with their own monitoring of kidney and liver tests.

Growth factors are medicines that mimic the body’s own signals to make blood cells. Erythropoiesis-stimulating agents encourage red cell production, and granulocyte colony-stimulating factors boost neutrophils. Response is judged on the CBC, and the eight-week sustained-improvement rule from the 2006 International Working Group criteria is the yardstick teams use to decide whether the medicine is doing its job.

Hypomethylating agents are a class of medicines that alter how genes are switched on in marrow cells; they are widely used in higher-risk MDS. A feature worth knowing in advance is that counts often fall during the first cycles before any improvement appears, so early weeks involve frequent bloods, sometimes weekly, and clear instructions about fever. Meaningful responses typically take several cycles to emerge, and teams usually plan a marrow re-assessment after a defined number rather than judging by a single count. Whatever the treatment, the following weeks tend to be a period of closer contact, more frequent draws and a lower threshold for calling, which then eases as the pattern settles.

Living between visits: reading your own results without alarm

Most hospitals now release results to patient portals, sometimes before the clinician has seen them. That transparency is welcome, and it can also be a source of needless midnight worry. A few principles help.

Trend beats snapshot. Look at the graph, not the latest number. A platelet count that reads 88 one day and 96 the next has not meaningfully changed; laboratory analyzers have a normal margin of variation, and hydration, time of day and recent illness all nudge values. Most teams regard a change as real only when it persists across two or more draws, and the eight-week sustained-response standard used in MDS research reflects that same caution.

Know your own baseline. Reference ranges printed on a report describe healthy people, so almost every MDS result will carry a flag. The relevant question is not whether a value is flagged but whether it has moved relative to your usual. Writing your typical hemoglobin, neutrophil and platelet values on a card, as the man in the cafe did with his pen, turns a page of alarming red highlights into a quick three-point check.

Keep a transfusion and infection log. The date and pre-transfusion hemoglobin for each unit, and the dates of any fevers or courses of antibiotics, give your team information the laboratory cannot. Shortening transfusion intervals and clustering infections are both signals of change that a CBC alone may under-report.

Iron matters even when you feel fine. If you receive transfusions, ask what your ferritin is and how it is trending; iron overload is silent until it is not. And protect the marrow you have: the NHS advice on avoiding infection, keeping vaccinations up to date as advised by your team, and seeking prompt care for fevers applies throughout observation, not just during treatment.

What people often get wrong about MDS monitoring

Some misunderstandings surface so often in clinic that they deserve direct correction.

Myth: a normal-looking blood count means the MDS has gone. Counts can stabilize or improve, particularly with treatment, while the clone remains in the marrow. The International Working Group criteria distinguish hematologic improvement, which is about counts, from marrow response, which requires a marrow sample. A better CBC is good news; it is not the same as an absent disease.

Myth: watch and wait means the team is doing nothing. Observation is a deliberate strategy backed by the NHS and Mayo Clinic for lower-risk disease, chosen because treatments carry side effects and because many people in low-risk groups remain stable for long periods. The waiting is structured, with defined triggers for action.

Myth: every drop in counts means progression. Infections, medications, dehydration and laboratory variation move counts all the time. A single fall prompts a repeat, not a conclusion. Progression is diagnosed by a pattern across visits and usually confirmed by marrow examination.

Myth: MDS always turns into leukemia. It can, and monitoring exists partly for that reason, but both the Mayo Clinic and the NHS are clear that many people, particularly in lower-risk groups, never experience that transformation.

Myth: a marrow biopsy is needed at every check-up. It is not routine in stable disease. It is repeated for specific reasons: changed counts, treatment decision points, suspected progression or transplant planning.

Myth: mutations found on a gene panel mean the disease is high risk. Some mutations carry prognostic weight; others are common in healthy older adults. Interpretation belongs with the hematologist, who reads them alongside counts, blasts and chromosomes rather than in isolation.

Myth: feeling well means the counts must be fine. Anemia in particular can develop slowly enough that the body adapts, and neutropenia causes no symptoms at all until an infection arrives. This is why the schedule of blood counts holds even when a person feels perfectly normal.

Questions to ask your care team

A follow-up visit goes better with a short list in hand. These questions are drawn from what people with MDS most often wish they had asked earlier.

• Which IPSS-R risk group am I in, and which of my results placed me there?
• What are my baseline hemoglobin, neutrophil and platelet values, and how much change from them would concern you?
• How often will my blood counts be checked, and what would make you shorten or lengthen that interval?
• Am I being observed or treated, and what specific finding would move me from one to the other?
• Under what circumstances would you repeat my bone marrow examination?
• Did my marrow include chromosome and gene testing, and did any of those results change my risk group or the plan?
• If I receive transfusions, how will you track iron overload, and at what point would you discuss iron-removing treatment?
• Which symptoms should prompt a same-day call, and which can wait for the next appointment?
• How should I prepare for treatment-related dips in counts, and who do I contact out of hours?
• Is a second pathology review or a repeat marrow planned if my diagnosis was described as early or borderline?
• What is the plan if my counts improve: does the monitoring schedule change, and does treatment continue?
• Are there clinical trials in monitoring or treatment that might be relevant to my situation?

Write the answers down or ask permission to record the conversation. Hematology visits carry a lot of numbers, and the MedlinePlus patient resources are a reliable place to re-read the basics between appointments. Bringing a family member or friend helps too; a second set of ears catches the qualifiers, such as whether a change is expected or worrying, that a worried patient tends to miss.

When to call your doctor

Most changes in MDS unfold slowly and are caught on scheduled blood counts. A few do not, and they map neatly onto the three cell lines the counts track. Low neutrophils mean infections can escalate within hours; low platelets mean bleeding may not stop on its own; a fast fall in hemoglobin strains the heart. The NHS is explicit that people with MDS should seek urgent advice for signs of infection, and the same urgency applies to bleeding.

Call your hematology team the same day, or use their out-of-hours line, for any of the following:

• A temperature of 38 degrees Celsius (100.4 degrees Fahrenheit) or higher, shivering, or feeling suddenly unwell even without a measured fever, especially if your neutrophils are known to be low or you are in the early cycles of treatment.
• Bleeding that does not stop after ten minutes of pressure, blood in urine or stool, black tarry stools, coughing or vomiting blood, or a sudden shower of tiny red or purple spots on the skin.
• Breathlessness at rest or on minimal exertion, chest pain, palpitations, or fainting, which can signal a rapid drop in hemoglobin or strain on the heart.
• A severe headache, confusion, sudden weakness on one side, or vision change, since these can indicate bleeding in a person with low platelets.
• Unusual bruising in places you have not knocked, or bruises appearing faster than they fade.
• Any new symptom that worries you between scheduled visits; teams would far rather hear about a false alarm than miss a real one.

Call emergency services rather than the clinic for collapse, uncontrolled bleeding, severe chest pain or difficulty breathing. Keep a card with your diagnosis, latest counts and the team’s contact numbers; if you attend an emergency department, showing it speeds decisions considerably.

For non-urgent matters, such as a portal result that looks different or a question about a transfusion date, a message or call within office hours is appropriate. Every decision about what a result means, and what to do about it, sits with your treating team; the purpose of this list is simply to make sure they hear from you in time.

Frequently asked questions

What labs are abnormal with MDS?

Low hemoglobin is the most common abnormality, often with larger-than-normal red cells shown by a raised MCV. Low neutrophils and low platelets may occur alone or together. The blood smear may show dysplastic cell shapes or occasional blasts. Supporting tests can include a low reticulocyte count, raised LDH and, in transfused people, rising ferritin. Which lines are affected differs from person to person, so the pattern matters more than any single value.

Is MDS a blood cancer?

Yes. MDS is classified as a cancer of the blood-forming cells in the bone marrow, as both the NHS and the Mayo Clinic describe. It is a clonal disease, meaning the faulty cells descend from one ancestor with acquired genetic changes. It behaves very differently from solid tumors, with no lump or scan finding, and severity ranges from mild count reductions watched over years to higher-risk disease that can progress toward acute myeloid leukemia.

What are the signs MDS is progressing?

On blood tests, the early signs are falling counts in more than one cell line, shortening transfusion intervals and the appearance of blasts on the smear. In daily life, people may notice fatigue that no longer improves after transfusion, recurring infections, unexplained bruising or bleeding, fevers or night sweats. None of these alone confirms progression; they prompt a repeat count and usually a marrow examination, which the treating team interprets.

How often is MDS misdiagnosed?

No reliable single percentage exists in mainstream guidance, and quoting one would be misleading. What is well established is that MDS is difficult to diagnose because vitamin B12 or folate deficiency, alcohol, certain medications, viral infections and recent chemotherapy can all produce dysplastic-looking marrow cells. Guidance therefore requires excluding these causes first, and borderline cases are often confirmed by following blood counts over several months.

How often are MDS blood test results checked during watch and wait?

There is no fixed interval in published patient guidance; the NHS and Mayo Clinic describe regular blood tests without specifying a schedule. Teams set the interval based on risk group, how stable previous counts have been, any treatment and other health conditions. Stable very low or low risk disease may be checked at intervals of several months, while recent changes or new treatment bring more frequent draws. Ask your team what would shorten the gap.

How often is a bone marrow biopsy repeated in MDS?

Not on a routine timer in stable disease. A repeat marrow is usually done for a specific reason: an unexplained fall in counts or new blasts on the smear, a baseline before starting treatment, a response assessment after a defined number of treatment cycles, suspected progression, or planning for stem cell transplant. Blast percentage and chromosome changes can only be measured in marrow, which is why these triggers require it.

Can a normal blood count mean MDS has gone away?

No. Counts can improve, especially with treatment, while the abnormal clone persists in the marrow. The International Working Group criteria separate hematologic improvement, which describes counts, from marrow response, which requires a marrow sample showing reduced blasts and dysplasia. A better CBC is genuinely good news and may change the monitoring interval, but only the treating team can say what it means for the disease itself.

Why does my team check ferritin at MDS follow-up visits?

Because red cell transfusions deliver iron that the body has no way to excrete. Over many units, iron accumulates and can damage the liver, heart and endocrine glands, a process the NHS highlights as a recognized complication. Ferritin is a blood protein that reflects stored iron, so a rising trend flags overload before organ damage occurs and helps the team decide whether to discuss iron-removing treatment.

What does the IPSS-R risk score use from my blood counts?

The Revised International Prognostic Scoring System, published in Blood in 2012, uses hemoglobin, platelet count and absolute neutrophil count from the CBC, together with marrow blast percentage and chromosome findings. Hemoglobin is scored across thresholds of 8 and 10 grams per deciliter, platelets at 50 and 100, and neutrophils at 0.8 (in thousands per microliter). The combined score places a person in one of five risk groups that guide monitoring and treatment discussions.

Why do my counts sometimes fall in the first weeks of MDS treatment?

Several MDS treatments, particularly hypomethylating agents, act on the marrow and commonly lower counts during early cycles before any improvement appears. This expected dip is why teams schedule frequent blood draws, sometimes weekly, at the start and give clear instructions about fever and bleeding. Meaningful responses typically take several cycles to show, and the prescribing clinician judges them against sustained changes rather than any single result.

References

• NHS: Myelodysplasia (myelodysplastic syndrome)
• MedlinePlus: Myelodysplastic syndromes

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.